{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:27:49Z","timestamp":1721780869763},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,22]]},"DOI":"10.7759\/cureus.65151","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T03:11:37Z","timestamp":1721704297000},"source":"Crossref","is-referenced-by-count":0,"title":["Discoloration and Dilemma: A Case Report of Hand-Foot Syndrome Associated With Capecitabine Use"],"prefix":"10.7759","author":[{"given":"Rucha","family":"Gohil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalyan","family":"Bojanapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerthi","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner B","year":"2001","unstructured":"Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001, 40:85-104. 10.2165\/00003088-200140020-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20174602","article-title":"Do you know this syndrome? Hand-foot syndrome","volume":"92","author":"Braghiroli CS","year":"2017","unstructured":"Braghiroli CS, Ieiri R, Ocanha JP, Paschoalini RB, Miot HA. Do you know this syndrome? Hand-foot syndrome. An Bras Dermatol. 2017, 92:131-3. 10.1590\/abd1806-4841.20174602","journal-title":"An Bras Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.546342","article-title":"Capecitabine and hand-foot syndrome","volume":"10","author":"Saif MW","year":"2011","unstructured":"Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf. 2011, 10:159-69. 10.1517\/14740338.2011.546342","journal-title":"Expert Opin Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2016.12.001","article-title":"The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome","volume":"49","author":"Chen M","year":"2017","unstructured":"Chen M, Chen J, Peng X, et al.. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol. 2017, 49:81-8. 10.1016\/j.etap.2016.12.001","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2022.05.004","article-title":"Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome - a literature review","volume":"98","author":"Nascimento AD","year":"2023","unstructured":"Nascimento AD, Porto DM, Vidal AK. Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome - a literature review. An Bras Dermatol. 2023, 98:302-9. 10.1016\/j.abd.2022.05.004","journal-title":"An Bras Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000001487","article-title":"Predictive factors for the development of capecitabine-induced hand-foot syndrome: a retrospective observational cohort study","volume":"86","author":"Chantharakhit C","year":"2024","unstructured":"Chantharakhit C, Sujaritvanichpong N. Predictive factors for the development of capecitabine-induced hand-foot syndrome: a retrospective observational cohort study. Ann Med Surg (Lond). 2024, 86:73-7. 10.1097\/MS9.0000000000001487","journal-title":"Ann Med Surg (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26891","article-title":"Hand-foot syndrome presentation post-capecitabine treatment in a Black patient","volume":"14","author":"Whorton AE","year":"2022","unstructured":"Whorton AE, Razzak AN, Jha P. Hand-foot syndrome presentation post-capecitabine treatment in a Black patient. Cureus. 2022, 14:e26891. 10.7759\/cureus.26891","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06353-2","article-title":"Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study)","volume":"23","author":"Santhosh A","year":"2022","unstructured":"Santhosh A, Kumar A, Pramanik R, et al.. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). Trials. 2022, 23:420. 10.1186\/s13063-022-06353-2","journal-title":"Trials"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02411-w","article-title":"Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)","volume":"22","author":"Iimura Y","year":"2022","unstructured":"Iimura Y, Furukawa N, Ishibashi M, et al.. Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). BMC Gastroenterol. 2022, 22:341. 10.1186\/s12876-022-02411-w","journal-title":"BMC Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1078155206069242","article-title":"Management of hand-foot syndrome induced by capecitabine","volume":"12","author":"Gressett SM","year":"2006","unstructured":"Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006, 12:131-41. 10.1177\/1078155206069242","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/271189-discoloration-and-dilemma-a-case-report-of-hand-foot-syndrome-associated-with-capecitabine-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T03:11:42Z","timestamp":1721704302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/271189-discoloration-and-dilemma-a-case-report-of-hand-foot-syndrome-associated-with-capecitabine-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.65151","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}